Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-08-26
1999-10-05
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
4241871, 4242071, 514 2, 514185, A61K 31395
Patent
active
059624469
ABSTRACT:
A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, -(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5063238 (1991-11-01), Sunkara et al.
patent: 5380746 (1995-01-01), Barth et al.
patent: 5481003 (1996-01-01), Gillig et al.
patent: 5491242 (1996-02-01), Gillig et al.
patent: 5516915 (1996-05-01), Barth et al.
patent: 5545636 (1996-08-01), Heath et al.
patent: 5552396 (1996-09-01), Heath et al.
patent: 5621098 (1997-04-01), Heath et al.
Lindholm, et al., "Human T-Cell Lymphotrophic Virus Type 1 Tax.sub.1 Activation of NF-.kappa.B: Involvement of the Protein Kinase C Pathway," J. Virol., vol. 70, No. 4, 2525-2532, 1996.
Daniela Saggioro et al. "Tax-Induced HTLV-1 LTR Transcriptional Activation is Modulated by Phosphorylation" Biochemical and Biophysical Research Communications, vol. 205, No. 1, Nov. 30, 1994, pp. 666-673.
Sandra E. Wilkinson et al. "Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C" Biochem J. (1993) 294 pp. 335-337.
Adchi et al., Biochem. Biophys. Res. Commun. 169: 469-475, 1990.
Arima et al., J. Virology 65: 6892-6899, 1991.
H. Bundgaard, Design of Prodrugs, (1985).
Gessain et al., Lancet II: 407-410, 1985.
Hinuma et al., PNAS 78: 6476-6480, 1981.
Jensen et al., J. Virology 66: 4427-4433, 1992.
Leung et al., Nature 333: 776-778, 1988.
Lindholm et al., New Biol. 2: 1034-1043, 1990.
Lindholm et al., J. Virology 70: 2525-2532, 1996.
Osame et al., Lancet I: 1031-1032, 1986.
Poiesz et al., PNAS 77: 7415-7419, 1980.
Smith et al., J. Clin. Invest. 87: 761-766, 1991.
Tan et al., Mol. Cell. Biol. 9: 1733-1745, 1989.
Yoshimura et al., EMBO J 9: 2537-2542, 1990.
Jirousek Michael R.
Stramm Lawrence E.
Ways Douglas Kirk
Budens Robert D.
Darkes Paul R.
Eli Lilly and Company
LandOfFree
Therapetutic treatment for human T cell lymphotrophic virus type does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapetutic treatment for human T cell lymphotrophic virus type, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapetutic treatment for human T cell lymphotrophic virus type will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1171612